CMR Surgical is reportedly seeking a $4 billion sale, according to the Financial Times. The U.K.-based robotic surgery firm has engaged advisors to explore strategic options, signaling a major move in the evolving surgical robotics landscape.
What’s Driving the Potential Sale:
- FDA-cleared Versius robot aims for broad U.S. expansion.
- Recent $200M funding round in April fuels global growth.
- Over 30,000 surgeries completed worldwide using Versius.
- The company is second only to Intuitive in install base and procedure volume.
Versius offers a modular, open-platform alternative to legacy systems, with patented biomimetic tech and ergonomic features. The system’s regulatory clearance across the U.S., Europe, Australia, and Brazil makes it ripe for global scaling.
Industry expert Steve Bell, a former CMR executive, calls the system “highly differentiated” and believes its acquisition would instantly position a buyer as the #2 player in soft tissue robotics.
A sale would reflect both CMR’s commercial maturity and growing consolidation in surgical robotics as strategic buyers seek proven, scalable platforms.
Follow MEDWIRE.AI for updates on surgical robotics innovation.
